See more : Salona Global Medical Device Corporation (LNDZF) Income Statement Analysis – Financial Results
Complete financial analysis of Hemostemix Inc. (HEM.V) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hemostemix Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Teladoc Health, Inc. (4LL.F) Income Statement Analysis – Financial Results
- Quebecor Inc. (QBCRF) Income Statement Analysis – Financial Results
- AVADA Group Limited (AVD.AX) Income Statement Analysis – Financial Results
- Aurizon Holdings Limited (AZJ.AX) Income Statement Analysis – Financial Results
- Otco International Limited (OTCO.BO) Income Statement Analysis – Financial Results
Hemostemix Inc. (HEM.V)
About Hemostemix Inc.
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 223.00 | 495.00 | 1.10K | 2.45K | 1.69K | 0.00 | 0.00 | 0.00 | 36.88K | 0.00 | 0.00 |
| Gross Profit | -223.00 | -495.00 | -1.10K | -2.45K | -1.69K | 0.00 | 0.00 | 0.00 | -36.88K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 384.89K | 622.65K | 179.90K | 650.05K | 2.35M | 2.26M | 60.26K | 828.58K | 1.49M | 1.56M | 285.82K |
| General & Administrative | 1.33M | 3.50M | 5.98M | 6.81M | 2.34M | 4.16M | 2.75M | 2.31M | 1.85M | 2.39M | 1.02M |
| Selling & Marketing | 620.31K | 459.00K | 493.27K | 288.41K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.95M | 3.95M | 6.47M | 6.81M | 2.34M | 4.16M | 2.75M | 2.31M | 1.85M | 2.39M | 1.02M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.16M | 4.58M | 6.66M | 7.47M | 4.70M | 6.42M | 2.81M | 3.71M | 3.98M | 4.29M | 1.53M |
| Cost & Expenses | 2.16M | 4.58M | 6.66M | 7.47M | 4.70M | 6.42M | 2.81M | 3.71M | 3.98M | 4.29M | 1.53M |
| Interest Income | 556.12 | 0.00 | 73.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 350.31K | 10.49K | 106.05K | 104.98K | 0.00 | 1.14M | 2.28K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 223.00 | 495.00 | 1.10K | 2.45K | 1.69K | 6.42M | 38.23K | 38.56K | 36.88K | 31.82K | 25.65K |
| EBITDA | -1.95M | -4.39M | -6.45M | -7.47M | -4.76M | 241.64K | -2.37M | -2.68M | -3.93M | -4.29M | -1.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.33M | -4.58M | -6.67M | -7.47M | -4.70M | -6.64M | -2.81M | -3.71M | -4.00M | -4.32M | -1.51M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -168.57K | -170.54K | 114.32K | -302.14K | -173.62K | 459.81K | -700.76K | -142.22K | 19.38K | -539.52K | 17.81K |
| Income Before Tax | -2.50M | -4.75M | -6.54M | -7.77M | -4.87M | -6.18M | -3.51M | -3.79M | -3.96M | -4.32M | -1.51M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 486.92K | -255.78K | 106.05K | 104.98K | 6.22K | -60.16K | -10.30K | 22.75K | 9.30K | 25.64K |
| Net Income | -2.50M | -5.24M | -6.29M | -7.77M | -4.87M | -6.19M | -3.93M | -3.78M | -3.99M | -4.33M | -1.54M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.07 | -0.11 | -0.24 | -0.32 | -0.41 | -0.56 | -1.12 | -1.13 | -1.39 | -0.50 |
| EPS Diluted | -0.03 | -0.07 | -0.11 | -0.24 | -0.32 | -0.41 | -0.56 | -1.12 | -1.13 | -1.39 | -0.50 |
| Weighted Avg Shares Out | 82.50M | 69.98M | 57.45M | 32.24M | 15.04M | 14.93M | 6.98M | 3.37M | 3.52M | 3.11M | 3.05M |
| Weighted Avg Shares Out (Dil) | 82.50M | 69.98M | 57.45M | 32.24M | 15.04M | 14.93M | 6.98M | 3.37M | 3.52M | 3.11M | 3.05M |
Source: https://incomestatements.info
Category: Stock Reports